LI

Lb Pharmaceuticals, Inc.

www.lbpharma.us link_icon

LB Pharmaceuticals Inc. Market Research Report



Company Overview



  • Name: LB Pharmaceuticals Inc.

  • Mission: To develop novel therapies that improve patient outcomes and address significant unmet medical needs in neuropsychiatric disorders.

  • Founded: 2015

  • Founders: No information is available

  • Key People:

  • Zachary Prensky: Chief Executive Officer

  • Andrew Vaino: Chief Scientific Officer

  • Roger Sawhney: Chief Financial Officer

  • Anna Eramo: Chief Medical Officer

  • Scott Garland: Chairman of the Board of Directors

  • Dr. Robert Ruffolo: Independent Director

  • Ran Nussbaum: Managing Partner and Co-Founder, Pontifax

  • Rebecca Luse: Principal, Deep Track Capital, LP

  • Dr. Rajul Jain: Managing Director, Vida Ventures

  • Dr. Chen Yu: Founder and Managing Partner, TCGX

  • Location: 575 Madison Avenue, New York, NY 10022

  • Number of Employees: No information is available

  • Revenue: No information is available

  • Known For: Developing novel, patent-protected therapies for neuropsychiatric diseases including schizophrenia.


Products



LB-102



  • Description: LB-102 is a novel, patent-protected methylated derivative of amisulpride, aimed to improve its therapeutic profile.

  • Key Features:

  • Improved Dosing and Safety: Achieves dopamine receptor occupancy in the brain comparable to amisulpride at significantly lower doses, resulting in potential safety improvements.

  • Tolerability: LB-102 is well-tolerated and potentially offers longer-term efficacy improvements.

  • Receptor Binding: Similar to amisulpride, LB-102 has low binding to 5-HT2C, Alpha-1, or H1 receptors, potentially reducing side effects like anti-cholinergic effects, weight gain, and sedation.

  • Once-Daily Dosing: LB-102 is being developed for once-daily dosing, making it easier for patients to adhere to their treatment plans.

  • Potential for Broader Efficacy: Aims to be more effective and better tolerated than most existing first-line treatments for schizophrenia, especially in addressing positive, negative, and cognitive symptoms.


Recent Developments



Recent Developments


  • Clinical Trials: Currently conducting a Phase 2 clinical trial (NCT06179108) to test LB-102 in patients with acute schizophrenia, evaluating its efficacy and safety.

  • Partnerships: No information is available

  • New Features Added:

  • Clinical studies have demonstrated that LB-102 achieves prolonged dopamine receptor engagement.

  • Clinical data shows superior dopamine receptor occupancy and improved efficacy at lower doses compared to amisulpride.


Publications and Presentations


  • ASCP 2024: "LB-102, a novel benzamide for the treatment of schizophrenia: safety and dopamine receptor occupancy data from two clinical studies."

  • Springer Nature Psychopharmacology, July 2022: "A randomized, double‑blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB‑102."

  • ACNP 2021: "PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor engagement."

  • ECNP 2021: "LB-102 displays superior dopamine receptor occupancy compared to amisulpride in mouse and human PET studies."

  • ECNP 2020: "Safety, pharmacokinetics, and pharmacodynamics of LB-102, a selective D2/5-HT7 antagonist, in healthy volunteers."

  • ECNP 2019: "Building a translational bridge from animals to man for clinical candidate LB-102, a next-generation benzamide antipsychotic."

  • ACS Omega 2019: "Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5‑HT7."

  • ECNP 2018: "LB-102, Potential Schizophrenia Treatment, Displays Polypharmacology as a Racemate—S Enantiomer Binds D2 Receptors and R Binds 5-HT7Receptor."

  • SOBP May 2018: "Establishing a PK-PD-E Relationship for Clinical Candidate LB-102, a Next-Generation Benzamide Antipsychotic."

  • ECNP Sept 2017: "Pre-clinical Evaluation of Two Novel Benzamides LB-102 and 103 for the Treatment of Schizophrenia."


Contact Information


  • Address: 575 Madison Avenue, New York, NY 10022

  • Phone Number: 646-588-8175

  • Website: No information is available


No information is available for several fields, but those which were provided have been thoroughly incorporated into this detailed report.